文献速递妇科

宫颈细胞学异常女性阴道镜检查中行宫颈管搔刮术诊断宫颈癌前病变

Diagnosis of Cervical Precancers by Endocervical Curettage at Colposcopy of Women With Abnormal Cervical Cytology.
PubMed 文献 · Obstet Gynecol · 2017-01-01

该研究为俄克拉荷马大学健康科学中心2009至2012年开展的横断面研究(Biopsy Study)的二次分析,评估常规宫颈管搔刮术(ECC)对宫颈上皮内瘤变2级及以上(CIN2+)及额外癌前病变的诊断效能。204名30岁及以上女性中181人(88.7%)接受ECC,总体ECC检出CIN2+为14.4%(95%CI 10.0-20.2%)。在最多4处宫颈外口活检基础上,ECC额外检出CIN2+仅3.9%(95%CI 1.9-7.8%)。

要点

  • 30岁及以上女性ECC总体检出CIN2+为14.4%(95%CI 10.0-20.2%)。
  • 高级别细胞学、HPV-16阳性或高级别阴道镜印象者ECC更易发现宫颈管内病变(P<.05)。
  • 最多4处活检后ECC额外检出CIN2+仅3.9%(95%CI 1.9-7.8%),且活检数越少额外检出越高(P<.05)。

核心结论

  • 在最多4处宫颈外口活检的阴道镜检查中,ECC额外检出CIN2+的收益低。
  • 作者建议:45岁及以上HPV-16感染者,以及任何30岁及以上伴HSIL或更严重或ASC-H细胞学、高级别阴道镜印象、或ASC-US或LSIL细胞学且检查不满意者,行常规ECC。

研究设计与样本

  • Biopsy Study的二次分析,该研究为2009至2012年在俄克拉荷马大学健康科学中心开展的横断面研究。
  • 204名30岁及以上女性中181人(88.7%)接受ECC。
  • 按细胞学、阴道镜印象、HPV-16状态、检查是否满意及ECC指征分层分析ECC单独检出CIN2+的收益。

主要发现

  • ECC总体检出CIN2+为14.4%(95%CI 10.0-20.2%)。
  • 高级别细胞学、HPV-16阳性或高级别阴道镜印象者ECC更易发现宫颈管内病变(各自P<.05)。
  • ASC-US或LSIL细胞学且检查不满意者ECC检出CIN2+为13.0%(95%CI 6.1-25.7%);阴道镜检查正常或满意且可见异常病变者ECC检出CIN2+低于5%。
  • ASC-H或HSIL或更严重细胞学者ECC检出CIN2+为25.8%(95%CI 16.6-37.9%)。
  • 在最多4处可见醋酸白宫颈外口病变活检累积检出病变之外,ECC额外检出CIN2+仅3.9%(95%CI 1.9-7.8%);活检数越少ECC额外检出CIN2+越高(P<.05)。

关键数值与推荐

  • ECC总体CIN2+检出率14.4%(95%CI 10.0-20.2%)。
  • ASC-US或LSIL细胞学且检查不满意者ECC检出CIN2+为13.0%(95%CI 6.1-25.7%)。
  • ASC-H或HSIL或更严重细胞学者ECC检出CIN2+为25.8%(95%CI 16.6-37.9%)。
  • 最多4处活检后ECC额外检出CIN2+为3.9%(95%CI 1.9-7.8%)。

临床怎么用

  • 作者建议对45岁及以上HPV-16感染者行常规ECC。
  • 作者建议对任何30岁及以上伴HSIL或更严重或ASC-H细胞学、高级别阴道镜印象、或ASC-US或LSIL细胞学且检查不满意者行常规ECC。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the performance of routine endocervical curettage (ECC) for diagnosing high-grade cervical intraepithelial neoplasia (CIN) 2 or worse and additional precancers not otherwise detected by ectocervical biopsies. METHODS: In a secondary analysis of the Biopsy Study, a cross-sectional study conducted between 2009 and 2012 at the University of Oklahoma Health and Sciences Center that found an incremental increase in detection of cervical precancers by multiple biopsies at colposcopy, ECC was performed in most women aged 30 years or older. Cervical intraepithelial neoplasia 2 or worse yield by ECC alone was evaluated in analyses stratified by cervical cytology (atypical squamous cells of undetermined significance [ASC-US] or low-grade squamous intraepithelial lesions [LSIL] compared with atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesions [ASC-H] or high-grade squamous intraepithelial lesions [HSIL] or worse), colposcopic impression (less than high-grade compared with high-grade), human papillomavirus (HPV)-16 infection status, whether the examination was satisfactory, and by ECC indications per the current guidelines for cervical cancer screening. The diagnostic value of ECC for detecting additional disease was evaluated by the number of lesion-directed ectocervical biopsies. RESULTS: Of the 204 women aged 30 years or older, 181 (88.7%) underwent ECC. Overall ECC detected 14.4% CIN 2 or worse (95% CI 10.0-20.2%). Endocervical curettage was more likely to find disease in the endocervix among women with high-grade cytology, positive HPV-16 infection, or high-grade colposcopic impressions (respective P values <.05). Among women with ASC-US or LSIL cytology, those with an unsatisfactory examination had a 13.0% CIN 2 or worse yield on ECC (95% CI 6.1-25.7); when colposcopic examination was normal or satisfactory with visible abnormal lesions, ECC detected less than 5% CIN 2 or worse in the endocervix. An ASC-H or HSIL or worse cytology was associated with a CIN 2 or worse yield of 25.8% by ECC (95% CI 16.6-37.9%). However, ECC found only 3.9% (95% CI 1.9-7.8%) additional CIN 2 or worse beyond the cumulative disease detected by up to four biopsies of visible acetowhite ectocervical lesions. Additional CIN 2 or worse yield by ECC increased when fewer lesion-directed biopsies were taken (P<.05). CONCLUSION: The additional yield of CIN 2 or worse by ECC in a colposcopy with up to four ectocervical biopsies was low. Based on our findings, we recommend routine ECC be performed in women aged 45 years old or older with HPV-16 infection and in any woman aged 30 years or older with HSIL or worse or ASC-H cytology, high-grade colposcopic impression, or ASC-US or LSIL cytology and an unsatisfactory examination. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT00339989.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Liu AH, Walker J, Gage JC, et al. Diagnosis of Cervical Precancers by Endocervical Curettage at Colposcopy of Women With Abnormal Cervical Cytology. Obstet Gynecol. 2017. PMID: 29112672. doi:10.1097/AOG.0000000000002330

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。